GLP1R and cardiovascular disorder: ("Glucagon-Like Peptide 1 Receptor Agonists"[MeSH] OR "GLP-1 receptor agonist" OR "Semaglutide" OR "Liraglutide" OR "Dulaglutide" OR "Exenatide" OR "Albiglutide" OR "Efpeglenatide" OR "Cotadutide" OR "Lixisenatide") AND ("Diabetes Mellitus, Type 2"[MeSH] OR "Type 2 Diabetes" OR "T2DM") AND ("Cardiovascular Diseases"[MeSH] OR "Major Adverse Cardiovascular Events" OR "MACE" OR "myocardial infarction" OR "stroke" OR "cardiovascular death")